Precigen (NASDAQ: PGEN)
Precigen Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Precigen Company Info
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
News & Analysis
2 Unmatched Stocks Wall Street Thinks Will Soar 152% or More in the Next 2 Years
Biotechs are capable of making huge gains in short periods, and they often do.
Why Precigen Stock Is Skyrocketing Today
A big partner is increasing its stake in the biopharmaceutical company.
Here's Why Intrexon Jumped 58% in June
The biotech is getting into the cannabinoids business.
Why Intrexon Stock Popped Today
A big deal with a medical cannabis company provided a spark for Intrexon.
Why Intrexon Stock Dropped 34% in March
Investors weren't happy to learn about its worsening cash position.
Here's What Caused Intrexon's 21% Rally Today
The company got welcome support from a big money manager.
Here's Why Intrexon Crashed (Again) Today
The company's burning through cash, and that has investors nervous.
Will Cannabis Producers Ditch Greenhouses for Bioreactors?
Plants aren't always the perfect medium for producing high-value compounds. Turns out, cannabinoids can be brewed with microbes instead of grown in plants.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.